<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS158949</article-id><article-id pub-id-type="doi">10.1101/2022.12.16.520801</article-id><article-id pub-id-type="archive">PPR586929</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Single-cell RNA sequencing analyses of primary cutaneous B-cell disorders reveal distinct molecular patterns consistent with clinical behavior</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Griss</surname><given-names>Johannes</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Drach</surname><given-names>Mathias C.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Vy</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Levine</surname><given-names>Jasmine P.</given-names></name><degrees>BA</degrees><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Thaler</surname><given-names>Felix M.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Medjimorec</surname><given-names>Marco A.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shaw</surname><given-names>Lisa E.</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mann</surname><given-names>Ulrike</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Weninger</surname><given-names>Wolfgang</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wagner</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wagner</surname><given-names>Stephan N.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Simonitsch-Klupp</surname><given-names>Ingrid</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Farlik</surname><given-names>Matthias</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jonak</surname><given-names>Constanze</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Brunner</surname><given-names>Patrick M.</given-names></name><degrees>MD, MSc</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Dermatology, Medical University of Vienna, Austria</aff><aff id="A2"><label>2</label>Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff><aff id="A3"><label>3</label>New York Medical College, Valhalla, NY, USA</aff><aff id="A4"><label>4</label>Department of Pathology, Medical University of Vienna, Austria</aff><author-notes><corresp id="CR1"><bold>Corresponding Authors:</bold> Patrick M. Brunner, MD, MSc, Associate Professor, Departmet of Dermatology, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029, <email>patrick.brunner@mountsinai.org</email>; Johannes Griss, MD, PhD, Associate Professor, Department of Dermatology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria, <email>johannes.griss@meduniwien.ac.at</email>, Telephone: +43 (0) 1 40400 77020, FAX: +43 (0) 1 40400 76990</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>23</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="preprint"><day>19</day><month>12</month><year>2022</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">CC BY-NC 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Cutaneous B-cell lymphomas (CBL) comprise a diverse group of diseases with variable clinical course and prognosis. The cellular and molecular mechanisms underlying the pathogenesis of CBL remain ill-defined. Here we performed single-cell RNA sequencing combined with B-cell and T-cell receptor sequencing in three distinct CBL entities. In contrast to benign cutaneous pseudolymphomas and healthy skin, each CBL variant contained a single dominant B-cell clone. In marginal zone lymphoproliferative disorder (MZLPD), expanded clones generally showed terminal differentiation along a physiological trajectory towards plasma cells and displayed transcriptomic profiles indistinguishable from the benign polyclonal bystander B-cells. Follicle center lymphoma (FCL) clones also exhibited a canonical B-cell marker profile but consisted of more homogeneous populations of proliferating and non-proliferating germinal center (GC) B-cell-like phenotypes. In the most aggressive CBL, diffuse large B-cell lymphoma, leg type (DCBCL-LT), cells revealed multiple non-physiological marker profiles as well as aberrant proliferative activity beyond conventional GC-like cells. Fibroblasts in MZLPD, FCL and pseudolymphomas, but not DLBCL-LT, expressed the classical chemotactic chemokine <italic>CXCL13.</italic> These data suggest that in cutaneous B-cell disorders other than DLBCL-LT, physiological immune circuits are primarily operative, consistent with their overall indolent behavior.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Primary cutaneous B-cell lymphomas comprise a heterogeneous group of extranodal non-Hodgkin lymphomas.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> The three most common subtypes include primary cutaneous marginal zone lymphoproliferative disorder<sup><xref ref-type="bibr" rid="R2">2</xref></sup> (MZLPD, also named primary cutaneous marginal zone lymphoma),<sup><xref ref-type="bibr" rid="R3">3</xref></sup> primary cutaneous follicle center lymphoma (FCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (DLBCL-LT).<sup><xref ref-type="bibr" rid="R1">1</xref></sup> MZLPD and FCL are highly indolent with a 5-year disease-specific survival of &gt;95%, while DLBCL-LT is associated with an aggressive disease course as reflected by a 5-year survival rate of less than 60%.<sup><xref ref-type="bibr" rid="R4">4</xref></sup></p><p id="P3">Previous gene expression analyses identified characteristic B-cell phenotypes in each of these diseases. MZLPD B cells were found to be most similar to plasma cells, FCL showed a more germinal center (GC)-like phenotype, and DLBCL-LT lesions were most consistent with activated B-cells.<sup><xref ref-type="bibr" rid="R5">5</xref>–<xref ref-type="bibr" rid="R7">7</xref></sup> A key challenge is that, in B-cell lymphomas, clonality is not always detectable using routine molecular methods, or when a surrogate such as light-chain restriction is used.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> In those instances, the differentiation from so-called pseudolymphomas can be difficult, as they are usually defined as non-clonal B-cell proliferations.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> Additionally, some authors suggest that especially MZLPD may develop from pre-existing, non-neoplastic lymphoid infiltrates,<sup><xref ref-type="bibr" rid="R10">10</xref></sup> adding another level of complexity to the diagnosis of cutaneous B-cell lymphomas. To distinguish these from pseudolymphomas, skin flow cytometry was found to have superior sensitivity than immunohistochemistry, <italic>in situ</italic> hybridization or immunoglobulin heavy chain gene rearrangement examinations. Nevertheless, its routine use is difficult as it requires fresh tissue, is prone to technical challenges during processing, and is not widely available.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> Thus, we urgently need a better cellular and molecular characterization of primary cutaneous B-cell neoplasms and pseudolymphomas to improve our understanding of their pathophysiology, and identify diagnostic and prognostic markers for improved patient care.</p><p id="P4">Here, we present an in-depth, single-cell RNA sequencing-based characterization of primary cutaneous B-cell lymphomas and pseudolymphomas. By combining this with B and T-cell receptor sequencing, we were able to clearly differentiate each condition on a molecular level.</p></sec><sec id="S2" sec-type="materials | methods"><title>Materials &amp; Methods</title><sec id="S3"><title>Patient recruitment and sample processing</title><p id="P5">Patients were recruited at the Medical University of Vienna, Austria. Skin punch biopsies were taken after obtaining written informed consent, under a protocol approved by the Ethics Committee of the Medical University of Vienna (EK 1360/2018). After processing using the Skin Dissociation Kit by Miltenyi Biotech (Bergisch Gladbach, Germany),<sup><xref ref-type="bibr" rid="R11">11</xref>–<xref ref-type="bibr" rid="R13">13</xref></sup> single-cell suspensions were subjected to scRNA-seq using the Chromium Single Cell Controller and Single Cell 5’ Library &amp; Gel Bead Kit v1.1 (10X Genomics, Pleasanton, CA) according to the manufacturer’s protocol. TCR and BCR sequences were enriched from cDNA using the VDJ Kit workflow by 10X Genomics. Sequencing was performed using the Illumina NovaSeq platform and the 150bp paired-end configuration.</p></sec><sec id="S4"><title>Data analysis</title><p id="P6">Preprocessing of the scRNA-seq data was performed using Cell Ranger version 6.1.2 (10x Genomics). Raw sequencing files were demultiplexed using the Cell Ranger command “mkfastq.” Each sample was aligned to the human reference genome assembly “refdata-gex-GRCh38-2020-A” using the Cell Ranger command “count”.</p><p id="P7">TCR and BCR sequences were processed using CellRanger’s “vdj” command. CellRanger’s clonotype assignments were used as a basis. Clonotypes that shared the same CDR3 sequence in one chain and did not differ in any other chain were merged.</p><p id="P8">Expression data was processed using R (version 4.2.1),<sup><xref ref-type="bibr" rid="R14">14</xref></sup> Seurat (version 4.0.5),<sup><xref ref-type="bibr" rid="R15">15</xref></sup> and monocle3 (version 1.0.0).<sup><xref ref-type="bibr" rid="R16">16</xref></sup> Plots were generated using Seurat and ggplot2 (version 3.3.5).<sup><xref ref-type="bibr" rid="R17">17</xref></sup> As initial quality control, cells with &lt;500 genes or &gt;20% mitochondrial genes were removed. Subsequently, <italic>MALAT1,</italic> mitochondrial and ribosomal genes, as well as immunoglobulin variable cluster and TCR variable genes were removed. Next, basic normalization and sample-specific bias removal was performed using Seurat’s scTransform on all samples from one disease group. For this step, the “method” parameter was set to “glmGamPoi” and “conserver.memory” was enabled. Variables to regress were set to % mitochondrial genes and the sample identifier. Disease group data was subsequently integrated using Seurat’s reciprocal principal component approach.<sup><xref ref-type="bibr" rid="R15">15</xref></sup> Integration markers were identified using the first 30 principal components and the number of anchors (“k.anchor”) set to 20. Dataset integration was subsequently performed using the first 30 principial components. Clustering was performed using Seurat’s “FindNeighbours” function to construct the nearest neighborhood graph, followed by the “FindClusters” function to identify distinct clusters. For the completely integrated dataset, this was done using the first 15 principial components for the non-lymphocytic subclustering and 30 principal components for the B-cell and T-cell subclustering, and a resolution of 0.5 for the T-cell clustering and 0.8 for the B cell and non-lymphocytic ones. Certain cell populations were further subclustered to identify smaller populations. These included NK cells/ILCs, proliferating T cells, <italic>CD4+</italic> T cells, and all major non-lymphocytic cell types. Here, the subclustering was performed by extracting the respective cells and re-running the PCA, the neighborhood graph creation, and the identification of clusters. This step used the first 15 principal components and a resolution of 0.1-0.5 depending on subset size.</p><p id="P9">Clustering results were then re-integrated into the original subclustering. Differential expression analysis was performed using Seurat’s FindMarkers function and the data in the “SCT” slot.</p><p id="P10">The trajectory/pseudotime analysis was performed using monocle3.<sup><xref ref-type="bibr" rid="R16">16</xref></sup> Here, the Seurat object was converted into monocle’s cds object. Clusters were identified based on the UMAP embedding. Subsequently terminally differentiated plasma cells were used as the starting point to derive the pseudotime, which was then inverted in order to match the canonical B-cell differentiation path.</p></sec><sec id="S5"><title>Multiplex Immunohistochemistry</title><p id="P11">Multiplex immunostainings were conducted as previously described.<sup><xref ref-type="bibr" rid="R18">18</xref></sup> Briefly, 4µm sections were deparaffinized and antigen retrieval was performed in heated citrate buffer (pH 6.0) and/or Tris-EDTA buffer (pH 9) for 30 min. Thereafter, sections were fixed with 7.5% neutralized formaldehyde (SAV Liquid Production GmbH, Flintsbach am Inn, Germany). Each section was subjected to 6 successive rounds of antibody staining, consisting of protein blocking with 20% normal goat serum (Dako, Glostrup, Denmark) in PBS, incubation with primary antibodies, biotinylated anti-mouse/rabbit secondary antibodies and Streptavidin-HRP (Dako), followed by TSA visualization with fluorophores Opal 520, Opal 540, Opal 570, Opal 620, Opal 650, and Opal 690 (PerkinElmer, Waltham, MA, USA) diluted in 1X Plus Amplification Diluent (PerkinElmer), Ab-TSA complex-stripping in heated citrate buffer (pH 6.0) and/or Tris-EDTA buffer (pH 9) for 30 minutes, and fixation with 7.5% neutralized formaldehyde. Thereafter, nuclei were counterstained with DAPI (PerkinElmer), and sections were mounted with PermaFluor fluorescence mounting medium (Thermo Fisher Scientific, Waltham, MA, USA). Multiplexed slides were scanned on a Vectra Multispectral Imaging System version 2 (Perkin Elmer). Briefly, a library from spectral peaks emitted by each fluorophore from single stained slides was created with the Advanced Image Analysis software (InForm 2.4, PerkinElmer) and used for spectral unmixing of multispectral images allowing for identification of all markers of interest. Autofluorescence was determined on an unstained representative study sample. After adaptive cell segmentation, cut-off values for each fluorophore/antibody staining were defined. All phenotyping and subsequent quantifications were performed blinded to the sample identity.</p></sec><sec id="S6"><title>Data Sharing Statement</title><p id="P12">Complete gene level expression and VDJ sequencing data of all newly analyzed samples will be made available on GEO. Data from healthy control samples in a previously published dataset from our laboratory are available under GEO accession number GSE173205.<sup><xref ref-type="bibr" rid="R11">11</xref></sup></p></sec></sec><sec id="S7" sec-type="results"><title>Results</title><sec id="S8"><title>Single-cell RNA sequencing map of primary cutaneous B-cell lymphomas, pseudolymphomas and healthy control individuals</title><p id="P13">Using single-cell RNA sequencing (scRNA-seq), we profiled 178,647 cells from skin biopsies of patients with clinical and histopathological diagnoses of primary cutaneous B-cell lymphomas, namely MZLPD (97,680 cells, n=7 patients), FCL (14,107 cells, n=1 patient), DLBCL-LT (13,387 cells, n=3 biopsies from 2 patients), in comparison to patients with idiopathic nodular B-cell pseudolymphomas<sup><xref ref-type="bibr" rid="R19">19</xref></sup> (PSEUDO, 36,163 cells, n=4 biopsies from 3 patients) and healthy control subjects (NHS, 17,310 cells, n=4 individuals, <xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Clustering analyses revealed diverse skin cell populations according to expression of canonical cell markers, including large numbers of B and T cells, as well as smaller populations of NK cells, myeloid dendritic cells (DCs), plasmacytoid dendritic cells (pDCs), macrophages (Macro), fibroblasts (FB), keratinocytes (KRT), smooth muscle cells (SMC), melanocytes (Mel), and blood and lymphatic endothelial cells (EC, LEC), (<xref ref-type="fig" rid="F1">Figure 1A-C)</xref>. While most cell types were found at varying numbers in all 5 groups, B cells and pDCs were essentially absent in NHS samples (<xref ref-type="fig" rid="F1">Figure 1D</xref>). Further subclustering of all B cells (<xref ref-type="fig" rid="F1">Figure 1E</xref>) revealed a diverse pool of differentiation stages, from naïve B cells <italic>(IGHD+),</italic> GC cells <italic>(CD38+AICDA+)</italic> to fully differentiated plasma cells <italic>(CD27+CD38+SDC1+IGHG1+IGHG4+)</italic> (<xref ref-type="fig" rid="F1">Figure 1E-F</xref>).</p><p id="P14">B cells from DLBCL-LT showed distant, separate clustering from other entities, while FCL was largely confined to GC-like cells (<xref ref-type="fig" rid="F1">Figure 1G</xref>). By contrast, MZLPD B cells were found across various different cell types, largely overlapping with pseudolymphomas (<xref ref-type="fig" rid="F1">Figure 1G</xref>). In order to characterize B-cell clonality of our samples, we combined scRNA-seq profiling with B-cell receptor (BCR) sequencing and depicted the single most abundant clone for each sample, colored for each disease group (<xref ref-type="fig" rid="F1">Figure 1H</xref>). High top clone numbers were found in DLBCL-LT, FCL and MZLPD, consistent with a clonal disease, while numbers were much lower in pseudolymphoma (<xref ref-type="fig" rid="F1">Figure 1H</xref>). While the top clones of DLBCL-LT and FCL showed distinct clustering, those from MZLPD and pseudolymphomas were largely overlapping (<xref ref-type="fig" rid="F1">Figure 1H</xref>). These data suggest a close transcriptomic relation between MZLPD and pseudolymphomas, when compared to FCL and DLBCL-LT.</p></sec><sec id="S9"><title>MZLPD shows distinctively expanded clones in contrast to pseudolymphoma samples</title><p id="P15">To better delineate potential differences between MZLPD and pseudolymphomas, we clustered each of these samples separately (<xref ref-type="fig" rid="F2">Figure 2A-B</xref>). In contrast to pseudolymphomas (<xref ref-type="fig" rid="F2">Figure 2A</xref>), MZLPD showed distinct clusters of the single most abundant clone in all samples (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Consistently, top clone numbers were considerably higher in MZLPD than in pseudolymphomas (<xref ref-type="fig" rid="F2">Figure 2C</xref>), and the gap from the first to the second most abundant clone was much larger in MZLPD than pseudolymphoma samples (<xref ref-type="fig" rid="F2">Figure 2D</xref>). This confirms the concept that MZLPD is a clonal process, while pseudolymphomas show a generally polyclonal B-cell receptor pattern, despite otherwise strong transcriptomic similarities.</p></sec><sec id="S10"><title>Expanded clones of MZLPD span several B-cell subsets</title><p id="P16">Given these similarities beyond the clonal expansion, and to facilitate a direct comparison, we separately subclustered B-cells of MZLPD and pseudolymphomas (<xref ref-type="fig" rid="F3">Figure 3A</xref>). This subclustering allowed us to phenotypically identify eleven different B-cell subtypes (<xref ref-type="fig" rid="F3">Figure 3A-B</xref>, <xref ref-type="supplementary-material" rid="SD2">Table S2</xref>). We found five clusters of naïve B cells, as defined by expression of <italic>CD19, MS4A1</italic> (CD20), and <italic>IGHD,</italic> while being negative for <italic>CD27</italic> and <italic>CD38</italic> (<xref ref-type="fig" rid="F3">Figure 3B</xref>). All naïve B cells expressed low, but noticeable levels of the B-cell activation gene <italic>CD83.</italic> Naïve 1 and 2 were further characterized by upregulation of MHC II genes, indicating early activation.<sup><xref ref-type="bibr" rid="R20">20</xref></sup> Naïve 3 showed an additional up-regulation of heat shock proteins and thus likely represent stressed activated B cells in the dataset.<sup><xref ref-type="bibr" rid="R21">21</xref></sup> Naïve 4 exhibited strong <italic>VPREB3</italic> expression, a known B-cell differentiation marker<sup><xref ref-type="bibr" rid="R22">22</xref></sup> that we also found in some GC B cells (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Therefore, naïve 4 might be most consistent with activated cells differentiating towards GC B cells. Naïve 5 were <italic>ATM+</italic> and partly <italic>BCL6+,</italic> both associated with V(D)J recombination.<sup><xref ref-type="bibr" rid="R23">23</xref></sup> Their embedding in close vicinity to memory cells (<xref ref-type="fig" rid="F3">Figure 3A</xref>) suggests very late <italic>IGHD+</italic> cells in the process of class switching. Besides this large pool of naïve B cells, we observed activated B cells with stronger <italic>CD83</italic> expression that further harbored the anti-apoptotic NF-κB target transcription factor gene <italic>BCL2A1</italic> and the chemokine ligand <italic>CCL4</italic>.<sup><xref ref-type="bibr" rid="R24">24</xref></sup> We were able to identify two distinct populations of <italic>CD38+AICDA+</italic> GC B cells: <italic>BCL6+</italic> cells (GC1), and an <italic>MKI67+</italic> population of proliferating B cells (GC2)<sup><xref ref-type="bibr" rid="R25">25</xref></sup> (<xref ref-type="fig" rid="F3">Figure 3A-B</xref>). We also found a comparably large fraction of <italic>CD27+, IGHD+</italic> and <italic>IGHG1</italic><sup>low</sup> B cells which most likely represent unswitched memory B cells, and, together with switched memory B cells <italic>(CD27+IGHE+IGHG4+)</italic> represent marginal zone B cells.<sup><xref ref-type="bibr" rid="R24">24</xref></sup> Finally, plasma cells <italic>(CD27+CD38+IGHG1+IGHG4+SDC1/CD138+)</italic> formed a clearly separated cluster (<xref ref-type="fig" rid="F3">Figure 3A-B</xref>). Importantly, clonally expanded B cells from MZLPD samples did not form a distinct population but spanned several cell clusters (<xref ref-type="fig" rid="F3">Figure 3C</xref>). These top abundant MZLPD clones were primarily found in (i) <italic>CD27+</italic> memory B cells, (ii) plasma cells and (iii) GC B cells (<xref ref-type="fig" rid="F3">Figure 3C</xref>). While frequencies of expanded clones increased towards more differentiated B-cell clusters, the opposite was found within the polyclonal infiltrate (<xref ref-type="fig" rid="F3">Figure 3D</xref>). However, the cluster distribution of these clones showed considerable patient-to-patient variation (<xref ref-type="fig" rid="F3">Figure 3E</xref>, <xref ref-type="supplementary-material" rid="SD3">Table S3</xref>), a finding consistent with the pathological observation that some, but not all, MZLPD lesions are dominated by plasma cell-like B cells, which have previously been classified as cutaneous immunocytomas.<sup><xref ref-type="bibr" rid="R26">26</xref></sup> While most MZLPD clones showed a switch towards IgG isotypes, sample 92 was characterized by <italic>IGHM</italic> and <italic>IGHE</italic> expression (<xref ref-type="fig" rid="F3">Figure 3F</xref>), consistent with the previously described rare form of IgM-dominant / uncommon class-switched MZLPD.<sup><xref ref-type="bibr" rid="R2">2</xref></sup> The expanded clone of sample 92 formed three distinct groups: two as part of the “switched memory” cluster and one as part of plasma cells (<xref ref-type="fig" rid="F3">Figure 3E</xref>). The cluster adjacent to “GC2” had a clearly proliferative component that was <italic>MS4A1</italic> (CD20) negative (<xref ref-type="fig" rid="F3">Figure 3G</xref>), a phenotype that is not typically seen in physiological B-cell development and differentiation.<sup><xref ref-type="bibr" rid="R27">27</xref></sup> Similarly, the second group in the “switched memory” fraction also contained an <italic>MS4A1</italic> negative portion (<xref ref-type="fig" rid="F3">Figure 3G</xref>). This kind of aberrant phenotype was not present in any other MZLPD sample (not shown), and might explain the potentially more aggressive behavior of non-switched or non-IgG switched MZL.<sup><xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R29">29</xref></sup> Generally, though, differential gene expression analysis between expanded clones and the polyclonal B-cell infiltrate in MZLPD samples did not reveal major differences. The analysis resulted in only 24 differentially expressed genes (DEGs) within the GC1 cluster, followed by as little as 13 DEGs in switched memory B cells (<xref ref-type="fig" rid="F3">Figure 3H</xref>, <xref ref-type="supplementary-material" rid="SD4">Table S4</xref>). These DEGs consisted of down-regulated MHC II genes <italic>(HLA-DRB1, HLA-DRA, HLA-DQA1, HLA-DQB1)</italic> and an up-regulation of <italic>IGLC3</italic> within the expanded clone, corresponding to the observed dominance of lambda chain positive lymphomas in our dataset (<xref ref-type="fig" rid="F2">Figure 2B</xref>, <xref ref-type="supplementary-material" rid="SD4">Table S4</xref>). Taken together, these minimal differences indicate that clonally expanded B cells were very similar to the respective subsets of polyclonal B cells.</p><p id="P17">To further assess the distribution of clonally expanded B cells on this differentiation path, we used Monocle3 to place all B cells on a pseudotime scale (<xref ref-type="fig" rid="F3">Figure 3I</xref>). This put naïve 1 (MHC II<sup>high</sup>) and activated B cells at the beginning of the differentiation scale, followed by naïve 2. Naïve 4 cells were similarly positioned as GC cells, followed by proliferating GC cells (<xref ref-type="fig" rid="F3">Figure 3I</xref>). Here, clustering positioned some switched memory B cells close to late GC B cells, suggesting that these late GC types differentiate towards memory B cells / early plasma cells. Naïve 5 were put on a similar pseudotime section as some memory B cells, which matches their assumed up-regulation of genes associated with V(D)J recombination.<sup><xref ref-type="bibr" rid="R23">23</xref></sup> Therefore, this pseudotime trajectory approximated the known B-cell differentiation path.<sup><xref ref-type="bibr" rid="R27">27</xref></sup> Importantly, cells of the expanded clone tightly followed this trajectory, with increasing canonical differentiation markers such as <italic>CD27, IGHE, IGHG1,</italic> and <italic>IGHG4</italic> during pseudotime (<xref ref-type="fig" rid="F3">Figure 3J</xref>). In each sample, these clonally expanded cells were distributed over a wide range of the pseudotime trajectory and ranged from naïve B cells to terminally differentiated plasma cells (<xref ref-type="fig" rid="F3">Figure 3K</xref>). This indicates that expanded clones of MZLPD generally follow the normal B-cell differentiation path and terminally differentiate within the skin.</p></sec><sec id="S11"><title>In contrast to MZLPD, expanded FCL clones only consisted of GC-like B cells</title><p id="P18">We next assessed whether other forms of primary cutaneous B-cell lymphomas also followed conventional B-cell differentiation trajectories. Clustering analysis of a biopsy from a primary cutaneous follicle center lymphoma (FCL) patient showed GC-like cells to dominate the B-cell population (<xref ref-type="fig" rid="F4">Figure 4A-C</xref>). In contrast to MZLPD, clonally expanded B cells were strictly confined to proliferating and non-proliferating <italic>CD38+, AICDA+</italic> GC B cells (<xref ref-type="fig" rid="F4">Figure 4B</xref>). By contrast, activated B cells only consisted of polyclonal cells (<xref ref-type="fig" rid="F4">Figure 4B</xref>). Similarly, a published FCL sample from a study on the effect of oncolytic virotherapy in cutaneous B-cell lymphoma<sup><xref ref-type="bibr" rid="R30">30</xref></sup> revealed the dominant clone also to be limited to proliferating and non-proliferating GC clusters, corroborating our results (<xref ref-type="fig" rid="F4">Figure 4D-G</xref>). From these data, we conclude that the expanded clones from primary cutaneous FCLs are confined to the histopathologically observed GC forming B cells.<sup><xref ref-type="bibr" rid="R31">31</xref></sup></p></sec><sec id="S12"><title>DLBCL-LT showed multiple aberrant B-cell phenotypes</title><p id="P19">We further profiled 3 samples from 2 DLBCL-LT patients (<xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="fig" rid="F5">Figure 5A</xref>). In contrast to expanded clones of MZLPD (<xref ref-type="fig" rid="F3">Figure 3</xref>) and FCL (<xref ref-type="fig" rid="F4">Figure 4</xref>), DLBCL-LT cells showed marker combinations that did not follow physiological B-cell phenotypes (<xref ref-type="fig" rid="F5">Figure 5B</xref>). Virtually all clonally expanded cells (<xref ref-type="fig" rid="F5">Figure 5C</xref>) showed expression of <italic>CD27,</italic> with widespread loss of <italic>MS4A1</italic> (CD20, <xref ref-type="fig" rid="F5">Figure 5D</xref>). There was no expression of late-stage differentiation markers like <italic>IGHE, IGHG1, IGHG4,</italic> and <italic>SDC1</italic> (CD138) (<xref ref-type="fig" rid="F5">Figure 5D</xref>). The large fraction of proliferating <italic>(MKI67+)</italic> cells included <italic>MS4A1-</italic> and <italic>CD38-</italic> cells (<xref ref-type="fig" rid="F5">Figure 5D</xref>), which do not typically exist under physiological conditions.<sup><xref ref-type="bibr" rid="R27">27</xref></sup> These findings were replicated in a published DLBCL-LT sample<sup><xref ref-type="bibr" rid="R30">30</xref></sup> (<xref ref-type="supplementary-material" rid="SD9">Figure S1A-D</xref>). There, malignant cells were again <italic>CD27+,</italic> with fractions showing a loss of <italic>MS4A1,</italic> and proliferating cells spanning several B-cell phenotypes (<xref ref-type="supplementary-material" rid="SD9">Figure S1D</xref>). Plasma cells and canonical <italic>IGHD+</italic> naïve B cells were only found in the polyclonal B-cell fraction (<xref ref-type="supplementary-material" rid="SD9">Figure S1D</xref>). In both datasets, malignant clones were not confined to specific cell clusters, but were found across all B-cell clusters at high proportions, while polyclonal cell counts were generally much lower in number (<xref ref-type="fig" rid="F5">Figure 5E</xref>, <xref ref-type="supplementary-material" rid="SD9">S1</xref>).</p><p id="P20">This was in stark contrast to FCL and MZLPD, where polyclonal B cells were consistently present at higher frequencies than the top expanded B-cell clone (<xref ref-type="fig" rid="F5">Figure 5F</xref>). The presence of considerably proliferating and dedifferentiated cells that do not correspond to canonical B-cell stages is very consistent with the clinical observation that DLBCL-LT is a more aggressive entity than FCL or MZLPD.</p></sec><sec id="S13"><title>In contrast to B cells, major T-cell populations did not differ between disease groups</title><p id="P21">Since T cells constituted the largest group of cells in our dataset, even outnumbering B-cell counts in most samples (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>), we further subclustered this population (<xref ref-type="supplementary-material" rid="SD9">Figure S2A</xref>). T-cell clusters consisted of diverse subpopulations of <italic>CD4+</italic> helper T cells, <italic>CD8A+</italic> cytotoxic T cells including a <italic>CCL4+IFNG+</italic> population, NKT cells, smaller clusters of <italic>FOXP3+</italic> regulatory T cells, <italic>NR4A2+TNFRSF18+TNFRSF4+</italic> activated T cells, exhausted <italic>CD4+PDCD1+TIGIT+</italic> T cells, <italic>MKI67+</italic> proliferating T cells, <italic>CD3D-KLRD1+</italic> NK cells and <italic>CD3D-KLRD1-KLRB1+</italic> innate lymphoid cells (ILCs) (<xref ref-type="supplementary-material" rid="SD9">Figure S2B</xref>, <xref ref-type="supplementary-material" rid="SD5">Table S5</xref>). In contrast to B cells that showed several non-overlapping clusters depending on the disease type (<xref ref-type="fig" rid="F1">Figure 1G</xref>), T lymphoid clusters were generally present in all conditions, albeit at lower levels and with less T-cell proliferation in NHS samples (<xref ref-type="supplementary-material" rid="SD9">Figure S2C</xref>). Overall, differential gene expression did not reveal major differences among groups, except for increased expression of cytotoxic molecules in DLBCL-LT compared to all other conditions (<xref ref-type="supplementary-material" rid="SD6">Table S6</xref>). When combining scRNA-seq with TCR sequencing, we found a generally polyclonal TCR pattern, with frequencies of top expanded clones in the range of NHS (<xref ref-type="supplementary-material" rid="SD9">Figure S2D</xref>). In contrast to the <italic>CD4</italic> dominance in NHS, lymphomas and pseudolymphomas showed the top clones to be primarily present in <italic>CD8A+</italic> cytotoxic populations, which might be consistent with a cytotoxic anti-lymphomatous immune reaction<sup><xref ref-type="bibr" rid="R32">32</xref></sup> (<xref ref-type="fig" rid="F7">Figure 7D</xref>). Nevertheless, we did not detect T-cell populations uniquely expanded in individual disease groups, as opposed to B cells.</p></sec><sec id="S14"><title>Multiplex immunohistochemistry showed a diverse B-cell infiltrate in MZLPD and pseudolymphomas in contrast to DLBCL-LT</title><p id="P22">As current scRNA-seq methods can be prone to sampling bias, we assessed B cell and T cell populations by using a multiplex immunohistochemistry (IHC) approach previously established at our center.<sup><xref ref-type="bibr" rid="R18">18</xref></sup> This panel allowed us to simultaneously characterize naïve-like B cells (CD19+/CD20+, CD27-, CD38-, CD138-), GC-like B cells (CD19+/CD20+, CD27-, CD38+, CD138-), memory-like B cells (CD19+/CD20+, CD27+, CD38-, CD138-), plasma cells (CD19+, C20-, CD138+), and T cells (CD19-/CD20-, CD5+). Overall, MZLPD and pseudolymphoma samples harbored a diverse lymphocytic infiltrate, as opposed to DLBCL-LT (<xref ref-type="fig" rid="F6">Figure 6A-B</xref>). While we observed all B-cell subtypes in pseudolymphomas and MZLPD samples, several DLBCL-LT samples only consisted of naïve-like CD19+ and CD20+ B cells. We further quantified phenotypic diversity of the infiltrate using the Shannon diversity index (<xref ref-type="fig" rid="F6">Figure 6C</xref>). This confirmed a significantly larger heterogeneity of lymphocyte composition in pseudolymphomas and MZLPD samples compared to DLBCL-LT, paralleling indolent <italic>vs.</italic> aggressive clinical disease behavior.<sup><xref ref-type="bibr" rid="R33">33</xref></sup></p></sec><sec id="S15"><title>Indolent B-cell lymphomas and pseudolymphomas are characterized by a <italic>CXCL13+</italic> fibroblast population</title><p id="P23">We also assessed non-lymphocytes and their distribution across diseases (<xref ref-type="fig" rid="F7">Figure 7A-B</xref>, <xref ref-type="supplementary-material" rid="SD7">Table S7</xref>). As expected, DCs and macrophages were significantly less frequent in NHS, consistent with a relative increase of fibroblast and melanocyte counts (<xref ref-type="fig" rid="F7">Figure 7C</xref>). While total fibroblast numbers were comparable across lymphomas and pseudolymphomas, <italic>CXCL13+</italic> fibroblasts were the only population consistently absent in all DLBCL-LT samples (<xref ref-type="fig" rid="F7">Figure 7D-E</xref>, <xref ref-type="supplementary-material" rid="SD9">S3</xref>), cells known to be key to B-cell recruitment in the tumor microenvironment<sup><xref ref-type="bibr" rid="R34">34</xref></sup> and infection.<sup><xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R36">36</xref></sup> All other subsets showed no significant difference in cell number between disease groups (<xref ref-type="supplementary-material" rid="SD9">Figure S3</xref>).</p><p id="P24">We further performed differential gene expression analysis comparing each cell type of one disease against the respective cells of the other three subtypes (<xref ref-type="fig" rid="F7">Figure 7F-G</xref>). Most differentially expressed genes in MZLPD and pseudolymphomas were found in keratinocytes (<xref ref-type="fig" rid="F7">Figure 7F-G</xref>). However, these were driven by single samples and correlated with clinically visible inflammation rather than the disease subset (not shown). FCL was dominated by down-regulated genes (<xref ref-type="fig" rid="F7">Figure 7F</xref>) which were rather caused by up-regulated genes in other samples (<xref ref-type="supplementary-material" rid="SD8">Table S8</xref>). The comparably large number of significantly up-regulated genes in DLBCL-LT (<xref ref-type="fig" rid="F7">Figure 7G</xref>) was driven by B cell and cell division associated genes, most likely originating from lysed tumor cells leading to ambient RNA contamination.<sup><xref ref-type="bibr" rid="R37">37</xref></sup> The largest number of non-B cell-associated genes was found in DCs, macrophages, and fibroblasts (<xref ref-type="fig" rid="F7">Figure 7F-G</xref>), mainly including inflammation-associated genes (<xref ref-type="supplementary-material" rid="SD8">Table S8</xref>). On closer inspection, we found that these differences were largely driven by single samples (not shown). Therefore, the major consistent disease specific difference on a cell population level was the lack of <italic>CXCL13+</italic> fibroblasts in DLBCL-LT, suggesting a potentially critical role in disease-specific B cell recruitment for these cells.</p></sec></sec><sec id="S16" sec-type="discussion"><title>Discussion</title><p id="P25">By using scRNA-seq analyses of primary cutaneous B-cell disorders, we were able to detect disease-specific features, primarily on the level of expanded B-cell clones. Transcriptomic properties of other cells, including T cells and stromal cells, were surprisingly homogeneous, without consistent differences across disease groups. In line with DLBCL-LT’s aggressive clinical behavior, DLBCL-LT clones consisted of highly aberrant B cells, in contrast to all other conditions investigated, which largely showed cellular phenotypes mimicking physiological cell populations. Specifically, the B-cell infiltrate in FCL was dominated by an expanded clone of relatively homogeneous GC B cells. By contrast, MZLPD clones spanned multiple B-cell phenotypes, indicating that these cells follow a physiological B-cell differentiation path towards end-differentiated plasma cell-like B cells that no longer proliferate. This observation supports the recently suggested re-classification of IgG class-switched marginal zone lymphoma as a lymphoproliferative disorder,<sup><xref ref-type="bibr" rid="R2">2</xref></sup> except for a small subset of IgM+/non-canonically class-switched MZLPD, which might still be regarded as a lymphoma due to frequent extracutaneous involvement.<sup><xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R38">38</xref></sup> In line, we found a single <italic>IGHM+</italic> MZLPD patient to show aberrant phenotypic features that were absent in class-switched MZLPD. Nevertheless, expanded clones of MZLPD could phenotypically not be differentiated from polyclonal B cells, further suggesting their close correlation with physiological phenotypes.<sup><xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R38">38</xref>–<xref ref-type="bibr" rid="R41">41</xref></sup> This might explain why many studies struggled to identify the putatively malignant clone in MZLPD,<sup><xref ref-type="bibr" rid="R30">30</xref></sup> which can make the differentiation from so-called pseudolymphomas particularly difficult.<sup><xref ref-type="bibr" rid="R19">19</xref></sup> For this reason, there is an ongoing debate whether some pseudolymphomas might merely represent lymphomas that have not yet been correctly diagnosed due to lack of sensitivity of routine diagnostic methods.<sup><xref ref-type="bibr" rid="R42">42</xref></sup> However, we consistently found that pseudolymphomas harbored a clearly polyclonal B-cell pattern, in contrast to MZLPD. Nevertheless, longitudinal studies will be necessary to investigate whether these patients will eventually develop overt lymphomas, or whether they retain their polyclonal, non-malignant characteristics.</p><p id="P26">The fact that expanded clones in FCL and MZLPD samples did not differ significantly from physiological, polyclonal B cells might also suggest a generally physiological mechanism of recruitment of these cells to the skin. Interestingly, we detected a distinct population of <italic>CXCL13+</italic> fibroblasts in FCL, MZLPD, and pseudolymphomas, but not in DLBCL-LT or healthy control skin. By expressing this prominent B-cell attracting chemokine, these fibroblasts might have a role in chemotaxis of the observed B cell infiltrates in pseudolymphomas and indolent lymphoma groups,<sup><xref ref-type="bibr" rid="R34">34</xref>–<xref ref-type="bibr" rid="R36">36</xref></sup> but not DCBCL-LT. In line, DLBCL-LT showed a much less diverse B-cell infiltrate than pseudolymphomas or MZLPD and was rather dominated by monomorphous B-cell populations. Taken together, this investigation is the first comprehensive molecular map of primary B-cell lymphoproliferative disorders in humans, which might help guide future treatment approaches for these skin conditions.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Table S1</label><media xlink:href="EMS158949-supplement-Table_S1.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d91aAdEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Table S2</label><media xlink:href="EMS158949-supplement-Table_S2.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d91aAdEcB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>Table S3</label><media xlink:href="EMS158949-supplement-Table_S3.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d91aAdEdB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><label>TABLE S4</label><media xlink:href="EMS158949-supplement-TABLE_S4.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d91aAdEeB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD5"><label>Table S5</label><media xlink:href="EMS158949-supplement-Table_S5.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d91aAdEfB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD6"><label>Table S6</label><media xlink:href="EMS158949-supplement-Table_S6.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d91aAdEgB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD7"><label>Table S7</label><media xlink:href="EMS158949-supplement-Table_S7.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d91aAdEhB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD8"><label>Table S8</label><media xlink:href="EMS158949-supplement-Table_S8.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d91aAdEiB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD9"><label>Supplementary Figures</label><media xlink:href="EMS158949-supplement-Supplementary_Figures.pdf" mimetype="application" mime-subtype="pdf" id="d91aAdEjB" position="anchor"/></supplementary-material></sec></body><back><ack id="S17"><title>Acknowledgements</title><p>This work was funded by a research grant to PMB from the Austrian Science Fund (grant number KLI 849-B). SNW was supported by a research grant from the Austrian Science Fund (grant number P31127). JG was supported by a research grant from the Austrian Science Fund (P35937).</p></ack><fn-group><fn id="FN1" fn-type="con"><p id="P27"><bold>Authorship contributions</bold></p><p id="P28">Conceptualization, C.J., J.G., P.M.B.; Software and Formal Analysis, J.G., V.N.; Visualization: J.G., J.P.L., F.M.T.; Investigation, C.J., C.W., J.G., I.S.K., L.E.S., M.A.M., M.C.D., M.F., P.M.B., S.N.W., U.M.; Resources, P.M.B., M.F., W.W.; Writing -Original Draft C.J., J.G., P.M.B.; Writing – Review &amp; Editing by all co-authors; Project Administration &amp; Supervision, C.J., J.G., M.F.; P.M.B., Funding Acquisition, P.M.B.</p></fn><fn id="FN2" fn-type="conflict"><p id="P29"><bold>Disclosure of Conflicts of Interest</bold></p><p id="P30">JG received personal fees from AbbVie and Novartis. CJ has received personal fees from Boehringer Ingelheim, LEO, Pfizer, Recordati Rare Diseases, Eli Lilly, Novartis, Takeda, Kyowa Kirin, Amgen, Sandoz, UCB, BMS, AbbVie, Janssen, and Almirall. CJ is an investigator for Eli Lilly, Novartis, 4SC, and Innate. WW has received personal fees from LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Boehringer Ingelheim, AbbVie, and Janssen. PMB has received personal fees from Almirall, Sanofi, Janssen, Amgen, LEO Pharma, AbbVie, Pfizer, Boehringer Ingelheim, GSK, Regeneron, Eli Lilly, Celgene, Arena Pharma, Novartis, UCB Pharma, Biotest and BMS. PMB is an investigator for Pfizer. MF is involved in an ongoing collaboration with Böhringer Ingelheim. The rest of the authors declare that they have no relevant conflicts of interest.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term>MZLPD</term><def><p>Marginal zone lymphoproliferative disorder</p></def></def-item><def-item><term>MZL</term><def><p>Marginal zone lymphoma</p></def></def-item><def-item><term>FCL</term><def><p>Follicle center lymphoma</p></def></def-item><def-item><term>DLBCL-LT</term><def><p>Diffuse large B-cell lymphoma, leg type</p></def></def-item><def-item><term>scRNA-seq</term><def><p>Single-cell RNA sequencing</p></def></def-item><def-item><term>TCR</term><def><p>T-cell receptor</p></def></def-item><def-item><term>BCL</term><def><p>B-cell lymphoma</p></def></def-item><def-item><term>PSEUDO</term><def><p>Pseudolymphoma</p></def></def-item><def-item><term>HC</term><def><p>Healthy control</p></def></def-item></def-list></glossary><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willemze</surname><given-names>R</given-names></name><name><surname>Cerroni</surname><given-names>L</given-names></name><name><surname>Kempf</surname><given-names>W</given-names></name><etal/></person-group><article-title>The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas</article-title><source>Blood</source><year>2019</year><volume>133</volume><issue>16</issue><fpage>1703</fpage><lpage>1714</lpage><pub-id pub-id-type="pmcid">PMC6473500</pub-id><pub-id pub-id-type="pmid">30635287</pub-id><pub-id pub-id-type="doi">10.1182/blood-2018-11-881268</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Jaffe</surname><given-names>ES</given-names></name><name><surname>Cook</surname><given-names>JR</given-names></name><etal/></person-group><article-title>The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee</article-title><source>Blood</source><year>2022</year><pub-id pub-id-type="pmcid">PMC9479027</pub-id><pub-id pub-id-type="pmid">35653592</pub-id><pub-id pub-id-type="doi">10.1182/blood.2022015851</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="web"><collab>14]</collab><source>WHO classification of tumours series</source><edition>5th ed</edition><volume>11</volume><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://tumourclassification.iarc.who.int/chapters/63.WCoTEBHtIbvaopLFIAfRoCcD">https://tumourclassification.iarc.who.int/chapters/63.WCoTEBHtIbvaopLFIAfRoCcD</ext-link></comment></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitiello</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Ronchi</surname><given-names>A</given-names></name><name><surname>Caccavale</surname><given-names>S</given-names></name><name><surname>Franco</surname><given-names>R</given-names></name><name><surname>Argenziano</surname><given-names>G</given-names></name></person-group><article-title>Primary Cutaneous B-Cell Lymphomas: An Update</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>651</fpage><pub-id pub-id-type="pmcid">PMC7266949</pub-id><pub-id pub-id-type="pmid">32528871</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2020.00651</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>M</given-names></name></person-group><article-title>Cutaneous primary B-cell lymphomas: from diagnosis to treatment</article-title><source>An Bras Dermatol</source><year>2015</year><volume>90</volume><issue>5</issue><fpage>687</fpage><lpage>706</lpage><pub-id pub-id-type="pmcid">PMC4631235</pub-id><pub-id pub-id-type="pmid">26560215</pub-id><pub-id pub-id-type="doi">10.1590/abd1806-4841.20153638</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storz</surname><given-names>MN</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Mraz-Gernhard</surname><given-names>S</given-names></name><name><surname>Hoppe</surname><given-names>RT</given-names></name><name><surname>Kohler</surname><given-names>S</given-names></name></person-group><article-title>Gene expression profiles of cutaneous B cell lymphoma</article-title><source>J Invest Dermatol</source><year>2003</year><volume>120</volume><issue>5</issue><fpage>865</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">12713594</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoefnagel</surname><given-names>JJ</given-names></name><name><surname>Vermeer</surname><given-names>MH</given-names></name><name><surname>Jansen</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases</article-title><source>Arch Dermatol</source><year>2005</year><volume>141</volume><issue>9</issue><fpage>1139</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">16172311</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolay</surname><given-names>JP</given-names></name><name><surname>Wobser</surname><given-names>M</given-names></name></person-group><article-title>Cutaneous B-cell lymphomas -pathogenesis, diagnostic workup, and therapy</article-title><source>J Dtsch Dermatol Ges</source><year>2016</year><volume>14</volume><issue>12</issue><fpage>1207</fpage><lpage>1224</lpage><pub-id pub-id-type="pmid">27992127</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>Y</given-names></name><name><surname>Hamada</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Analysis of clonality in cutaneous B-cell lymphoma and B-cell pseudolymphoma using skin flow cytometry: Comparison of immunophenotyping and gene rearrangement studies</article-title><source>J Dermatol</source><year>2021</year><pub-id pub-id-type="pmid">34263482</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hristov</surname><given-names>AC</given-names></name><name><surname>Comfere</surname><given-names>NI</given-names></name><name><surname>Vidal</surname><given-names>CI</given-names></name><name><surname>Sundram</surname><given-names>U</given-names></name></person-group><article-title>Kappa and lambda immunohistochemistry and in situ hybridization in the evaluation of atypical cutaneous lymphoid infiltrates</article-title><source>J Cutan Pathol</source><year>2020</year><volume>47</volume><issue>11</issue><fpage>1103</fpage><lpage>1110</lpage><pub-id pub-id-type="pmid">32870521</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rindler</surname><given-names>K</given-names></name><name><surname>Jonak</surname><given-names>C</given-names></name><name><surname>Alkon</surname><given-names>N</given-names></name><etal/></person-group><article-title>Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma</article-title><source>Mol Cancer</source><year>2021</year><volume>20</volume><issue>1</issue><fpage>124</fpage><pub-id pub-id-type="pmcid">PMC8477535</pub-id><pub-id pub-id-type="pmid">34583709</pub-id><pub-id pub-id-type="doi">10.1186/s12943-021-01419-2</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangert</surname><given-names>C</given-names></name><name><surname>Rindler</surname><given-names>K</given-names></name><name><surname>Krausgruber</surname><given-names>T</given-names></name><etal/></person-group><article-title>Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Ralpha blockade</article-title><source>Sci Immunol</source><year>2021</year><volume>6</volume><issue>55</issue><pub-id pub-id-type="pmid">33483337</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojahn</surname><given-names>TB</given-names></name><name><surname>Vorstandlechner</surname><given-names>V</given-names></name><name><surname>Krausgruber</surname><given-names>T</given-names></name><etal/></person-group><article-title>Single-cell transcriptomics combined with interstitial fluid proteomics defines cell typespecific immune regulation in atopic dermatitis</article-title><source>J Allergy Clin Immunol</source><year>2020</year><volume>146</volume><issue>5</issue><fpage>1056</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">32344053</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="web"><source>R: A Language and Environment for Statistical Computing RCT</source><year>2022</year><comment><ext-link ext-link-type="uri" xlink:href="https://www.R-project.org">https://www.R-project.org</ext-link></comment></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Andersen-Nissen</surname><given-names>E</given-names></name><etal/></person-group><article-title>Integrated analysis of multimodal single-cell data</article-title><source>Cell</source><year>2021</year><volume>184</volume><issue>13</issue><fpage>3573</fpage><lpage>3587</lpage><elocation-id>e29</elocation-id><pub-id pub-id-type="pmcid">PMC8238499</pub-id><pub-id pub-id-type="pmid">34062119</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2021.04.048</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Reversed graph embedding resolves complex single-cell trajectories</article-title><source>Nat Methods</source><year>2017</year><volume>14</volume><issue>10</issue><fpage>979</fpage><lpage>982</lpage><pub-id pub-id-type="pmcid">PMC5764547</pub-id><pub-id pub-id-type="pmid">28825705</pub-id><pub-id pub-id-type="doi">10.1038/nmeth.4402</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><source>ggplot2 - Elegant Graphics for Data Analysis</source><edition>2nd Edition</edition><year>2016</year><comment>ISBN 9783319242774</comment></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griss</surname><given-names>J</given-names></name><name><surname>Bauer</surname><given-names>W</given-names></name><name><surname>Wagner</surname><given-names>C</given-names></name><etal/></person-group><article-title>B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>4186</fpage><pub-id pub-id-type="pmcid">PMC6744450</pub-id><pub-id pub-id-type="pmid">31519915</pub-id><pub-id pub-id-type="doi">10.1038/s41467-019-12160-2</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitteldorf</surname><given-names>C</given-names></name><name><surname>Kempf</surname><given-names>W</given-names></name></person-group><article-title>Cutaneous pseudolymphoma-A review on the spectrum and a proposal for a new classification</article-title><source>J Cutan Pathol</source><year>2020</year><volume>47</volume><issue>1</issue><fpage>76</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">31237707</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lankar</surname><given-names>D</given-names></name><name><surname>Vincent-Schneider</surname><given-names>H</given-names></name><name><surname>Briken</surname><given-names>V</given-names></name><name><surname>Yokozeki</surname><given-names>T</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name><name><surname>Bonnerot</surname><given-names>C</given-names></name></person-group><article-title>Dynamics of major histocompatibility complex class II compartments during B cell receptor-mediated cell activation</article-title><source>J Exp Med</source><year>2002</year><volume>195</volume><issue>4</issue><fpage>461</fpage><lpage>72</lpage><pub-id pub-id-type="pmcid">PMC2193618</pub-id><pub-id pub-id-type="pmid">11854359</pub-id><pub-id pub-id-type="doi">10.1084/jem.20011543</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonak</surname><given-names>C</given-names></name><name><surname>Klosner</surname><given-names>G</given-names></name><name><surname>Trautinger</surname><given-names>F</given-names></name></person-group><article-title>Heat shock proteins in the skin</article-title><source>Int J Cosmet Sci</source><year>2006</year><volume>28</volume><issue>4</issue><fpage>233</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">18489262</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felizola</surname><given-names>SJ</given-names></name><name><surname>Katsu</surname><given-names>K</given-names></name><name><surname>Ise</surname><given-names>K</given-names></name><etal/></person-group><article-title>Pre-B Lymphocyte Protein 3 (VPREB3) Expression in the Adrenal Cortex: Precedent for non-Immunological Roles in Normal and Neoplastic Human Tissues</article-title><source>Endocr Pathol</source><year>2015</year><volume>26</volume><issue>2</issue><fpage>119</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">25861052</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mensah</surname><given-names>KA</given-names></name><name><surname>Chen</surname><given-names>JW</given-names></name><name><surname>Schickel</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Impaired ATM activation in B cells is associated with bone resorption in rheumatoid arthritis</article-title><source>Sci Transl Med</source><year>2019</year><volume>11</volume><issue>519</issue><pub-id pub-id-type="pmcid">PMC7167286</pub-id><pub-id pub-id-type="pmid">31748230</pub-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaw4626</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>HW</given-names></name><name><surname>Orban</surname><given-names>N</given-names></name><name><surname>Riches</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Single-cell analysis of human B cell maturation predicts how antibody class switching shapes selection dynamics</article-title><source>Sci Immunol</source><year>2021</year><volume>6</volume><issue>56</issue><pub-id pub-id-type="pmid">33579751</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fagerberg</surname><given-names>E</given-names></name><etal/></person-group><article-title>Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses</article-title><source>Cell</source><year>2021</year><volume>184</volume><issue>25</issue><fpage>6101</fpage><lpage>6118</lpage><elocation-id>e13</elocation-id><pub-id pub-id-type="pmcid">PMC8671355</pub-id><pub-id pub-id-type="pmid">34852236</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2021.11.007</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>LM</given-names></name><name><surname>LeBoit</surname><given-names>PE</given-names></name></person-group><article-title>Are primary cutaneous immunocytoma and marginal zone lymphoma the same disease?</article-title><source>Am J Surg Pathol</source><year>1997</year><volume>21</volume><issue>11</issue><fpage>1368</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">9351575</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisel</surname><given-names>NM</given-names></name><name><surname>Joachim</surname><given-names>SM</given-names></name><name><surname>Smita</surname><given-names>S</given-names></name><etal/></person-group><article-title>Surface phenotypes of naïve and memory B cells in mouse and human tissues</article-title><source>Nat Immunol</source><year>2022</year><volume>23</volume><issue>1</issue><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="pmcid">PMC8712407</pub-id><pub-id pub-id-type="pmid">34937918</pub-id><pub-id pub-id-type="doi">10.1038/s41590-021-01078-x</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Flores</surname><given-names>A</given-names></name></person-group><article-title>Is there a narrow connection between the two subsets of cutaneous MALT lymphomas and the dynamics of the follicle?</article-title><source>Am J Dermatopathol</source><year>2013</year><volume>35</volume><issue>2</issue><fpage>283</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">22688395</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlsen</surname><given-names>ED</given-names></name><name><surname>Swerdlow</surname><given-names>SH</given-names></name><name><surname>Cook</surname><given-names>JR</given-names></name><name><surname>Gibson</surname><given-names>SE</given-names></name></person-group><article-title>Class-switched Primary Cutaneous Marginal Zone Lymphomas Are Frequently IgG4-positive and Have Features Distinct From IgM-positive Cases</article-title><source>Am J Surg Pathol</source><year>2019</year><volume>43</volume><issue>10</issue><fpage>1403</fpage><lpage>1412</lpage><pub-id pub-id-type="pmid">31464711</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramelyte</surname><given-names>E</given-names></name><name><surname>Tastanova</surname><given-names>A</given-names></name><name><surname>Balazs</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective</article-title><source>Cancer Cell</source><year>2021</year><volume>39</volume><issue>3</issue><fpage>394</fpage><lpage>406</lpage><elocation-id>e4</elocation-id><pub-id pub-id-type="pmid">33482123</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrader</surname><given-names>AMR</given-names></name><name><surname>de Groen</surname><given-names>RAL</given-names></name><name><surname>Willemze</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas</article-title><source>Virchows Arch</source><year>2022</year><volume>480</volume><issue>3</issue><fpage>667</fpage><lpage>675</lpage><pub-id pub-id-type="pmcid">PMC8990933</pub-id><pub-id pub-id-type="pmid">35028710</pub-id><pub-id pub-id-type="doi">10.1007/s00428-021-03265-5</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Adoptive CD8(+) T cell therapy against cancer:Challenges and opportunities</article-title><source>Cancer Lett</source><year>2019</year><volume>462</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">31356845</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsakiroglou</surname><given-names>AM</given-names></name><name><surname>Astley</surname><given-names>S</given-names></name><name><surname>Dave</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immune infiltrate diversity confers a good prognosis in follicular lymphoma</article-title><source>Cancer Immunol Immunother</source><year>2021</year><volume>70</volume><issue>12</issue><fpage>3573</fpage><lpage>3585</lpage><pub-id pub-id-type="pmcid">PMC8571143</pub-id><pub-id pub-id-type="pmid">33929583</pub-id><pub-id pub-id-type="doi">10.1007/s00262-021-02945-0</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>AB</given-names></name><name><surname>Peske</surname><given-names>JD</given-names></name><name><surname>Woods</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts</article-title><source>Cell Rep</source><year>2021</year><volume>36</volume><issue>3</issue><elocation-id>109422</elocation-id><pub-id pub-id-type="pmcid">PMC8362934</pub-id><pub-id pub-id-type="pmid">34289373</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109422</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denton</surname><given-names>AE</given-names></name><name><surname>Innocentin</surname><given-names>S</given-names></name><name><surname>Carr</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Type I interferon induces CXCL13 to support ectopic germinal center formation</article-title><source>J Exp Med</source><year>2019</year><volume>216</volume><issue>3</issue><fpage>621</fpage><lpage>637</lpage><pub-id pub-id-type="pmcid">PMC6400543</pub-id><pub-id pub-id-type="pmid">30723095</pub-id><pub-id pub-id-type="doi">10.1084/jem.20181216</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kogame</surname><given-names>T</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Kataoka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Possible inducible skin-associated lymphoid tissue (iSALT)-like structures with CXCL13(+) fibroblast-like cells in secondary syphilis</article-title><source>Br J Dermatol</source><year>2017</year><volume>177</volume><issue>6</issue><fpage>1737</fpage><lpage>1739</lpage><pub-id pub-id-type="pmid">28129667</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>MD</given-names></name><name><surname>Behjati</surname><given-names>S</given-names></name></person-group><article-title>SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data</article-title><source>Gigascience</source><year>2020</year><volume>9</volume><issue>12</issue><pub-id pub-id-type="pmcid">PMC7763177</pub-id><pub-id pub-id-type="pmid">33367645</pub-id><pub-id pub-id-type="doi">10.1093/gigascience/giaa151</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edinger</surname><given-names>JT</given-names></name><name><surname>Kant</surname><given-names>JA</given-names></name><name><surname>Swerdlow</surname><given-names>SH</given-names></name></person-group><article-title>Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets</article-title><source>Am J Surg Pathol</source><year>2010</year><volume>34</volume><issue>12</issue><fpage>1830</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">21107089</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Maldegem</surname><given-names>F</given-names></name><name><surname>van Dijk</surname><given-names>R</given-names></name><name><surname>Wormhoudt</surname><given-names>TA</given-names></name><etal/></person-group><article-title>The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment</article-title><source>Blood</source><year>2008</year><volume>112</volume><issue>8</issue><fpage>3355</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">18687986</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swerdlow</surname><given-names>SH</given-names></name></person-group><article-title>Cutaneous marginal zone lymphomas</article-title><source>Semin Diagn Pathol</source><year>2017</year><volume>34</volume><issue>1</issue><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">27986434</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guitart</surname><given-names>J</given-names></name></person-group><article-title>Rethinking primary cutaneous marginal zone lymphoma: shifting the focus to the cause of the infiltrate</article-title><source>J Cutan Pathol</source><year>2015</year><volume>42</volume><issue>9</issue><fpage>600</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">26011667</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charli-Joseph</surname><given-names>YV</given-names></name><name><surname>Gatica-Torres</surname><given-names>M</given-names></name><name><surname>Pincus</surname><given-names>LB</given-names></name></person-group><article-title>Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma?</article-title><source>Indian J Dermatol</source><year>2016</year><volume>61</volume><issue>4</issue><fpage>351</fpage><lpage>74</lpage><pub-id pub-id-type="pmcid">PMC4966394</pub-id><pub-id pub-id-type="pmid">27512181</pub-id><pub-id pub-id-type="doi">10.4103/0019-5154.185698</pub-id></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Key Points</title></caption><list list-type="bullet" id="L1"><list-item><p>This is the first comprehensive molecular map of primary cutaneous B-cell lymphoproliferative disorders.</p></list-item><list-item><p>Differences between entities were primarily geared by the expanded B-cell clone and less by other immune or stromal cells.</p></list-item></list></boxed-text><fig id="F1" position="float"><label>Figure 1</label><caption><title>Figure 1. Fig. 1: scRNA-seq map of B-cell lymphoma, pseudolymphoma and healthy control samples.</title><p><bold>(A)</bold> UMAP of unsupervised clustering of 178,647 cells integrated from primary cutaneous marginal zone lymphoproliferative disorder (MZLPD, n=7 patients), primary cutaneous follicle center lymphoma (FCL, n=1 patient), primary cutaneous diffuse large B-cell lymphoma leg-type (DLBCL-LT, n=3 biopsies from 2 patients), in comparison to patients with idiopathic nodular B-cell pseudolymphoma (PSEUDO, n=4 biopsies from 3 patients) and healthy control subjects (NHS, n=4 individuals) according to similarity of transcriptome, resulting in 14 different color-coded clusters. <bold>(B)</bold> Feature plots of individual patient groups. <bold>(C)</bold> Dot plots of cell clusters displaying average gene expression (red color) and frequency (circle size) of selected canonical cell type markers. <bold>(D)</bold> Relative distribution of major cell types across disease groups. <bold>(E)</bold> Sub-clustering of the entire B-cell population. <bold>(F)</bold> Dot plots of cell clusters displaying average gene expression (red color) and frequency (circle size) of selected canonical cell type markers of the subclustered B-cell population. <bold>(G)</bold> Feature plot of the B-cell population colored according to the disease group. <bold>(H)</bold> Feature plot displaying the top abundant B-cell clone of each sample, color coded for each disease group. UMAP: Uniform Manifold Approximation and Projection.</p></caption><graphic xlink:href="EMS158949-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Figure 2. Distribution and quantification of the single most abundant clone within individual MZLPD and pseudolymphoma samples.</title><p><bold>(A-B)</bold> Feature plots of (A) pseudolymphoma and (B) MZLPD samples clustered individually, without sample integration. Red: cells with the single most abundant BCR from each sample; single point mutations of the BCR sequence were considered to originate from the same clone; blue: cells with polyclonal BCR; grey: no BCR detected. <bold>(C)</bold> Absolute numbers of the single most abundant clone per sample and group, horizontal line denotes median. <bold>(D)</bold> Absolute numbers of the first 10 most abundant clones per denoted sample. UMAP: Uniform Manifold Approximation and Projection. BCR: B-cell receptor.</p></caption><graphic xlink:href="EMS158949-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Figure 3. Subclustering of B cells from MZLPD, pseudolymphoma and NHS samples.</title><p><bold>(A)</bold> UMAP of unsupervised sub-clustering of 51,723 cells integrated from initial B-cell clusters of primary cutaneous marginal zone lymphoma (MZL, n=7), pseudolymphoma (n=4) and healthy control individuals (n=4) according to similarity of transcriptome, resulting in 11 different color-coded clusters. <bold>(B)</bold> Dot plots of cell clusters displaying average gene expression (red color) and frequency (circle size) of selected canonical cell type markers. <bold>(C)</bold> Combined UMAP of cell clusters from MZLPD samples colored according to clonality of BCR. Red: cells with most abundant monoclonal BCR from each sample; blue: cells with polyclonal BCR; grey: no BCR detected. <bold>(D)</bold> Absolute numbers of clonally expanded B cells (red) and polyclonal B cells (blue) per cell cluster of MZLPD samples. <bold>(E)</bold> Feature plots of cell clusters colored according to clonality of BCR, showing individual MZLPD samples. <bold>(F)</bold> Dot plots displaying average gene expression (red color) and frequency (circle size) of selected immunoglobulin markers within the top abundant clone of each MZLPD sample. <bold>(G)</bold> Feature plots of sample #92 showing expression distribution for selected marker genes. Expression levels for each cell are color-coded and overlaid onto UMAP plots. Red color intensity represents the respective level of expression. <bold>(H)</bold> Number of DEGs within each cluster, comparing clonally expanded with</p><p>polyclonal B cells from MZLPD samples. Genes that were expressed in at least two samples per group and had an adjusted p value ≤0.01 and an absolute average log2 fold-change ≥0.8 were considered significantly regulated. <bold>(I)</bold> Monocle3 pseudotime trajectory within all B cell subclusters. <bold>(J)</bold> Normalized expression of selected canonical B cell developmental genes within top expanded clones of MZLPD samples according to pseudotime buckets from 1.99 to 12.4; cells are color-coded according to clustering. <bold>(K)</bold> Positioning of individual cells of the most abundant clone for MZLPD samples according to the pseudotime trajectory; cells are color-coded according to clustering. UMAP: Uniform Manifold Approximation and Projection. BCR: B-cell receptor.</p></caption><graphic xlink:href="EMS158949-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Follicle center lymphoma (FCL) shows germinal center clustering of the expanded clone.</title><p><bold>(A)</bold> UMAP of unsupervised clustering of 14,107 cells from a follicle center lymphoma sample according to similarity of transcriptome resulting in 12 different color-coded clusters. <bold>(B)</bold> Combined UMAP of cells colored according to clonality of BCR. Red: cells from the top expanded BCR; blue: cells with polyclonal BCR; grey: no BCR detected. <bold>(C)</bold> Dot plots of cell clusters displaying average gene expression (red color) and frequency (circle size) of selected canonical cell type markers. <bold>(D)</bold> UMAP of unsupervised clustering of 11,110 cells from the P12 follicle center lymphoma sample from Ramelyte et al.<sup><xref ref-type="bibr" rid="R30">30</xref></sup> <bold>(E)</bold> UMAP of cells from sample P12 with cells colored according to the clonality of the BCR. <bold>(F)</bold> Dot plots of canonical markers for the identified clusters from sample P12. <bold>(G)</bold> Absolute number of BCR positive cells from sample P12 per cell type, split by cells from the dominant clone and the remaining polyclonal infiltrate.</p></caption><graphic xlink:href="EMS158949-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Diffuse large B cell lymphoma samples show aberrant B cell phenotypes.</title><p><bold>(A)</bold> UMAP of unsupervised clustering of 13,387 cells integrated from 3 samples of diffuse large B-cell lymphoma, leg type, resulting in 18 different color-coded clusters. <bold>(B)</bold> Dot plots of cell clusters displaying average gene expression (red color) and frequency (circle size) of selected canonical cell type markers. <bold>(C)</bold> Combined UMAP of cell clusters colored for the most abundant BCR+ clone per sample. <bold>(D)</bold> Feature plots of expression distribution for selected marker genes. Expression levels for each cell are color-coded and overlaid onto UMAP plots. Red color intensity represents the respective level of expression. <bold>(E)</bold> Absolute numbers of clonally expanded B cells (red, yellow, purple) and polyclonal B cells (blue) per B-cell cluster and sample. <bold>(F)</bold> Percentages of expanded clones (red) vs the polyclonal B-cell infiltrate (blue) for each depicted sample.</p></caption><graphic xlink:href="EMS158949-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>Multicolor immunofluorescence assessment of diversity of B-cell subpopulations in pseudolymphoma, MZLPD, and DLBCL-LT samples.</title><p><bold>(A)</bold> Relative number of B-cell phenotypes per sample based on multicolor immunofluorescence quantification. <bold>(B)</bold> Representative pictures of multicolor immunohistochemistry staining of pseudolymphoma, MZLPD and DLBCL-LT samples. <bold>(C)</bold> Shannon entropy per sample to estimate the diversity of the cell compositions between the disease groups. DLBCL-LT samples showed a significantly reduced diversity compared to pseudolymphoma and MZLPD.</p></caption><graphic xlink:href="EMS158949-f006"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><title><italic>CXCL13+</italic> fibroblasts are absent in DLBCL-LT samples.</title><p><bold>(A)</bold> UMAP of unsupervised clustering of the 35,457 non-lymphoid cells integrated from all samples resulting in 19 different color-coded clusters. <bold>(B)</bold> Dot plots of cell clusters displaying average gene expression (red color) and frequency (circle size) of selected canonical cell type markers. <bold>(C)</bold> Combined UMAP of cell clusters split by sample group. <bold>(D)</bold> Absolute numbers of <italic>CXCL13</italic>+ fibroblasts for all disease groups. <bold>(E)</bold> Absolute numbers of the total fibroblast population for all disease groups. Upper and lower hinges correspond to the first and third quartiles. Upper and lower whiskers extend to the largest value within a maximum of 1.5 times the inter-quartile range. Colored points represent individual values. <bold>(F-G)</bold> Numbers of differentially expressed genes (F) downregulated or (G) upregulated per disease group within the depicted cluster.</p></caption><graphic xlink:href="EMS158949-f007"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Patient baseline characteristics at time of sampling.</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="top">Subject ID</th><th align="center" valign="top"/><th align="center" valign="top">Age</th><th align="center" valign="top">Sex</th><th align="center" valign="top">Race</th><th align="center" valign="top">Histopathological diagnosis</th><th align="center" valign="top">Location</th><th align="center" valign="top">Disease duration (years)</th><th align="center" valign="top">Ongoing treament</th><th align="center" valign="top">Previous treamtents</th><th align="center" valign="top">Disease stage</th></tr></thead><tbody><tr><td align="left" valign="middle">112</td><td align="left" valign="middle"/><td align="left" valign="middle">51</td><td align="left" valign="middle">F</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Healthy control</td><td align="left" valign="middle">Trunk</td><td align="left" valign="middle">n.a.</td><td align="left" valign="middle">n.a.</td><td align="left" valign="middle">n.a.</td><td align="left" valign="middle">n.a.</td></tr><tr><td align="left" valign="middle">115</td><td align="left" valign="middle"/><td align="left" valign="middle">48</td><td align="left" valign="middle">M</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Healthy control</td><td align="left" valign="middle">Trunk</td><td align="left" valign="middle">n.a.</td><td align="left" valign="middle">n.a.</td><td align="left" valign="middle">n.a.</td><td align="left" valign="middle">n.a.</td></tr><tr><td align="left" valign="middle">116</td><td align="left" valign="middle"/><td align="left" valign="middle">56</td><td align="left" valign="middle">F</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Healthy control</td><td align="left" valign="middle">Trunk</td><td align="left" valign="middle">n.a.</td><td align="left" valign="middle">n.a.</td><td align="left" valign="middle">n.a.</td><td align="left" valign="middle">n.a.</td></tr><tr><td align="left" valign="middle">121</td><td align="left" valign="middle"/><td align="left" valign="middle">44</td><td align="left" valign="middle">F</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Healthy control</td><td align="left" valign="middle">Trunk</td><td align="left" valign="middle">n.a.</td><td align="left" valign="middle">n.a.</td><td align="left" valign="middle">n.a.</td><td align="left" valign="middle">n.a.</td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="middle">92</td><td align="left" valign="middle"/><td align="left" valign="middle">72</td><td align="left" valign="middle">M</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Primary cutaneous marginal zone lymphoma/lymphoproliferative disorder</td><td align="left" valign="middle">Upper arm</td><td align="left" valign="middle">8 years</td><td align="left" valign="middle">None</td><td align="left" valign="middle">Rituximab</td><td align="left" valign="middle">T1bN0M0</td></tr><tr><td align="left" valign="middle">104</td><td align="left" valign="middle"/><td align="left" valign="middle">33</td><td align="left" valign="middle">M</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Primary cutaneous marginal zone lymphoma/lymphoproliferative disorder</td><td align="left" valign="middle">Trunk</td><td align="left" valign="middle">3 years</td><td align="left" valign="middle">None</td><td align="left" valign="middle">Clarithromycin</td><td align="left" valign="middle">T1bN0M0</td></tr><tr><td align="left" valign="middle">110</td><td align="left" valign="middle"/><td align="left" valign="middle">47</td><td align="left" valign="middle">M</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Primary cutaneous marginal zone lymphoma/lymphoproliferative disorder</td><td align="left" valign="middle">Trunk</td><td align="left" valign="middle">13 years</td><td align="left" valign="middle">None</td><td align="left" valign="middle">Rituximab</td><td align="left" valign="middle">T3aN0M0</td></tr><tr><td align="left" valign="middle">129</td><td align="left" valign="middle"/><td align="left" valign="middle">38</td><td align="left" valign="middle">M</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Primary cutaneous marginal zone lymphoma/lymphoproliferative disorder</td><td align="left" valign="middle">Shoulder</td><td align="left" valign="middle">14 years</td><td align="left" valign="middle">None</td><td align="left" valign="middle">Clarithromycin, surgery</td><td align="left" valign="middle">T3aN0M0</td></tr><tr><td align="left" valign="middle">146</td><td align="left" valign="middle"/><td align="left" valign="middle">47</td><td align="left" valign="middle">M</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Primary cutaneous marginal zone lymphoma/lymphoproliferative disorder</td><td align="left" valign="middle">Upper arm</td><td align="left" valign="middle">1 year</td><td align="left" valign="middle">None</td><td align="left" valign="middle">Surgery</td><td align="left" valign="middle">T1aN0M0</td></tr><tr><td align="left" valign="middle">172</td><td align="left" valign="middle"/><td align="left" valign="middle">72</td><td align="left" valign="middle">W</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Primary cutaneous marginal zone lymphoma/lymphoproliferative disorder</td><td align="left" valign="middle">Lower thigh</td><td align="left" valign="middle">2 years</td><td align="left" valign="middle">None</td><td align="left" valign="middle">Surgery, radiotherapy</td><td align="left" valign="middle">T1bN0M0</td></tr><tr><td align="left" valign="middle">WB3</td><td align="left" valign="middle"/><td align="left" valign="middle">60</td><td align="left" valign="middle">M</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Primary cutaneous marginal zone lymphoma/lymphoproliferative disorder</td><td align="left" valign="middle">Neck</td><td align="left" valign="middle">1 year</td><td align="left" valign="middle">None</td><td align="left" valign="middle">None</td><td align="left" valign="middle">T1bN0M0</td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="middle">99 + 159</td><td align="left" valign="middle"/><td align="left" valign="middle">30</td><td align="left" valign="middle">M</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Nodular cutaneous pseudolymphoma</td><td align="left" valign="middle">Upper arms</td><td align="left" valign="middle">1 year</td><td align="left" valign="middle">None</td><td align="left" valign="middle">None</td><td align="left" valign="middle">T3aN0M0</td></tr><tr><td align="left" valign="middle">134A</td><td align="left" valign="middle"/><td align="left" valign="middle">73</td><td align="left" valign="middle">M</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Nodular cutaneous pseudolymphoma</td><td align="left" valign="middle">Scalp</td><td align="left" valign="middle">11 years</td><td align="left" valign="middle">None</td><td align="left" valign="middle">Rituximab</td><td align="left" valign="middle">T2cN0M0</td></tr><tr><td align="left" valign="middle">166</td><td align="left" valign="middle"/><td align="left" valign="middle">47</td><td align="left" valign="middle">F</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Nodular cutaneous pseudolymphoma</td><td align="left" valign="middle">Face</td><td align="left" valign="middle">16 years</td><td align="left" valign="middle">None</td><td align="left" valign="middle">G lucocorticosteroids, hydroxychloroquine, apremilast</td><td align="left" valign="middle">T2cN0M0</td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="middle">198</td><td align="left" valign="middle"/><td align="left" valign="middle">77</td><td align="left" valign="middle">M</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Primary cutaneous follicle left lymphoma</td><td align="left" valign="middle">Scalp</td><td align="left" valign="middle">1 year</td><td align="left" valign="middle">None</td><td align="left" valign="middle">None</td><td align="left" valign="middle">T2aN0M0</td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="middle">206</td><td align="left" valign="middle"/><td align="left" valign="middle">74</td><td align="left" valign="middle">M</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Primary cutaneous diffuse large cell lymphoma, leg type</td><td align="left" valign="middle">Lower leg</td><td align="left" valign="middle">1 year</td><td align="left" valign="middle">None</td><td align="left" valign="middle">None</td><td align="left" valign="middle">T2bN0M0</td></tr><tr><td align="left" valign="middle">117 + 207</td><td align="left" valign="middle"/><td align="left" valign="middle">78</td><td align="left" valign="middle">F</td><td align="left" valign="middle">White</td><td align="left" valign="middle">Primary cutaneous diffuse large cell lymphoma, leg type</td><td align="left" valign="middle">Forearm and lower leg</td><td align="left" valign="middle">1 year</td><td align="left" valign="middle">None</td><td align="left" valign="middle">Radiotherapy, R-CHOP</td><td align="left" valign="middle">T3aN0M0</td></tr></tbody></table></table-wrap></floats-group></article>